KSA Group has taken another important step on the way to the new green building “Dreiklang”, KSA’s new ecological construction project. The KSA Group was able to raise CHF 120 million on the capital market
Private equity firm Astrog has entered into a binding agreement with privately owned industrial group International Chemical Investors Group (“ICIG”) whereby Astorg will acquire CordenPharma, a global pharmaceutical CDMO (Contract Development & Manufacturing Organisation) with
CDR-Life, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, has completed its Series A financing raising USD 76 million. The round was led by Jeito Capital and RA Capital
Groupe Bruxelles Lambert (GBL) acquires a majority stake in Sanoptis, a network of ophthalmology clinics across Germany and Switzerland, from the private equity
Versant Ventures debut Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies. Versant has made a USD 50m Series A commitment to Cimeio, which is the most recent start-up to emerge from
Bär & Karrer advised on the sale of Brust-Zentrum Zurich, a Swiss medical center specialised in the diagnosis and professional treatment of the breast. The owners of Brust-Zentrum Zurich have entered a strategic alliance
DentaCore, a privately held corporation specialising in acquisitions, investments and consolidation in the fragmented dental medicine sector, has acquired Cera-Tech, an innovative dental manufacturer. Headquartered in Switzerland, DentaCore focuses on the integration of outstanding practices,
Kellerhals Carrard acted as Swiss legal advisor to MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, in the closing of its previously announced business combination with Helix Acquisition Corp. (“Helix”), a
Kinarus, a privately owned clinical-stage biopharmaceutical company active in the development of novel treatments for patients suffering from serious viral, respiratory and ophthalmic diseases, signed a Transaction Agreement with SIX-listed Perfect Holding regarding Perfect Holding’
Ginkgo Bioworks, a horizontal platform for cell programming, entered into a definitive purchase agreement to acquire FGen, a Swiss company specializing in strain development and optimization. Ginkgo Bioworks believes that FGen’s technology will significantly
